Form 4: IGM Biosciences Director M. Kathleen Behrens Reports Acquisition of Shares Through Compensation Plan

IGM Biosciences Director M. Kathleen Behrens reported the acquisition of 1,471 shares of common stock as part of her quarterly retainer, increasing her total beneficial ownership to 382,535 shares.

Summary

• M. Kathleen Behrens, a Director at IGM Biosciences, Inc. (IGMS), reported the acquisition of 1,471 shares of common stock.
• The acquisition occurred on June 30, 2025, and was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.
• These shares are fully vested restricted stock units (RSUs) received as payment for a quarterly retainer under the Issuer's Outside Director Compensation Policy, with a reported price of $0.
• Following this transaction, M. Kathleen Behrens directly owns 22,222 shares of common stock.
• Additionally, she indirectly beneficially owns 330,700 shares through the KBW 2005 Trust, 29,807 shares through the Non-Exempt Trust for Patrick R. Wilsey, and 29,806 shares through the Non-Exempt Trust for Shannon K. Wilsey.
• The total beneficial ownership of common stock by M. Kathleen Behrens, including direct and indirect holdings, is 382,535 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake, aligning interests with shareholders. However, it is a routine compensation event rather than a discretionary purchase, which limits the strength of the positive signal.

Positives

• The acquisition of shares by a director aligns their interests with those of shareholders, demonstrating confidence in the company's future.
• The transaction is part of a pre-established compensation policy, indicating a structured and transparent approach to director remuneration.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report, common across all publicly traded industries, reflecting a director's compensation in equity. It does not provide specific insights into broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• M. Kathleen Behrens indirectly holds 330,700 shares through the KBW 2005 Trust, for which she is the Trustee.
• She indirectly holds 29,807 shares through the Non-Exempt Trust for Patrick R. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust, for which she is a Trustee.
• She indirectly holds 29,806 shares through the Non-Exempt Trust for Shannon K. Wilsey Under the Alfred S. Wilsey, Jr. Revocable Trust, for which she is a Trustee.

Stakeholder Impact

• Shareholders: The increase in director ownership through equity compensation can be viewed positively as it enhances alignment of interests between the board and shareholders.

Key Dates

Keywords

IGM Biosciences, IGMS, Form 4, Director Compensation, Restricted Stock Units, Insider Transaction, SEC Filing, Corporate Governance, Equity Compensation